Figures
- FIGURE 1
Overall mortality in the four treatment groups (placebo, fluticasone furoate (FF), vilanterol (VI) and FF/VI) according to previous treatment use. a) Those receiving no inhaled pre-treatment maintenance medication; b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use.
- FIGURE 2
Risk of moderate/severe exacerbations in the four treatment groups (placebo, fluticasone furoate (FF), vilanterol (VI) and FF/VI) according to previous treatment use. a) Those receiving no inhaled pre-treatment maintenance medication; b) those on inhaled corticosteroids and long-acting bronchodilators as previous treatment use. COPD: chronic obstructive pulmonary disease.
Tables
- TABLE 1
Baseline demographics according to previous treatment
No previous COPD medication Previous ICS only Previous LABD only Previous ICS/LABD Subjects 9423 643 1734 4617 Age years 64.7 64.3 66.1 66.0 BMI kg·m−2 27.5 28.7 28.7 28.6 Females 2325 (25%) 201 (31%) 429 (25%) 1231 (27%) Former smokers 4562 (48%) 383 (60%) 920 (53%) 2900 (63%) Smoking pack-years 40.0 37.8 43.6 41.5 Screening FEV1 % predicted 60.1 59.0 59.8 58.7 One or more exacerbations 3150 (33%) 416 (65%) 618 (36%) 2258 (49%) Region USA 1469 (16%) 63 (10%) 218 (13%) 803 (17%) Asia# 1961 (21%) 35 (5%) 121 (7%) 561 (12%) Europe 1¶ 2139 (23%) 88 (14%) 1175 (68%) 1872 (41%) Europe 2+ 3076 (33%) 352 (55%) 172 (10%) 1025 (22%) RoW§ 778 (8%) 105 (16%) 48 (3%) 356 (8%) Data are presented as mean, unless otherwise stated. COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroids; LABD: long-acting bronchodilators; BMI: body mass index; FEV1: forced expiratory volume in 1 s; RoW: rest of world. #: China, Indonesia, India, Japan, Korea, Malaysia, Philippines, Taiwan, Thailand and Vietnam; ¶: Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Greece, Hungary, Latvia, Netherlands, Poland, Romania, Slovakia, Spain, UK and Croatia; +: Bosnia and Herzegovina, Belarus, Georgia, Israel, Macedonia (Former Yugoslav Republic of), Russian Federation, Serbia, Turkey and Ukraine; §: Argentina, Australia, Canada, Chile, Columbia, Mexico and South Africa.
- TABLE 2
Time to first on-treatment moderate or severe exacerbation by previous treatment, grouped by long-acting bronchodilator (LABD) use
Placebo FF 100 µg VI 25 µg FF/VI 100/25 µg Total subjects 4111 4135 4118 4121 Subjects who did not receive LABD prior to the study None Subjects 2346 2405 2326 2346 Active versus placebo Hazard ratio (95% CI) 0.952 (0.852–1.065) 0.844 (0.752–0.947) 0.801 (0.713–0.900) Reduction in risk % (95% CI) 4.8 (−6.5–14.8) 15.6 (5.3–24.8) 19.9 (10.0–28.7) ICS alone Subjects 176 148 169 150 Active versus placebo Hazard ratio (95% CI) 0.889 (0.588–1.344) 1.180 (0.811–1.717) 0.877 (0.582–1.322) Reduction in risk % (95% CI) 11.1 (−34.4–41.2) −18.0 (−71.7–18.9) 12.3 (−32.2–41.8) Subjects who did receive LABD prior to the study LABD alone Subjects 464 406 449 415 Active versus placebo Hazard ratio (95% CI) 0.975 (0.772–1.230) 0.877 (0.697–1.103) 0.773 (0.609–0.981) Reduction in risk % (95% CI) 2.5 (−23.0–22.8) 12.3 (−10.3–30.3) 22.7 (1.9–39.1) ICS/LABD Subjects 1102 1164 1157 1194 Active versus placebo Hazard ratio (95% CI) 1.006 (0.877–1.154) 0.987 (0.861–1.132) 0.766 (0.665–0.882) Reduction in risk % (95% CI) −0.6 (−15.4–12.3) 1.3 (−13.2–13.9) 23.4 (11.8–33.5) FF: fluticasone furoate; VI: vilanterol; ICS: inhaled corticosteroid.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Figures S1 and S2 00203-2018_supp_figures
